$2.85
-0.10 (-3.23%)
Open$2.93
Previous Close$2.95
Day High$3.01
Day Low$2.85
52W High$13.93
52W Low$1.90
Volume—
Avg Volume21.0K
Market Cap6.46M
P/E Ratio—
EPS$-1.24
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+1,181.8% upside
Current
$2.85
$2.85
Target
$36.53
$36.53
$23.38
$36.53 avg
$47.42
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.84M | 3.19M | 899.1K |
| Net Income | -3,456,416 | -2,586,062 | -268,437 |
| Profit Margin | -90.1% | -85.6% | -29.9% |
| EBITDA | -3,654,741 | -2,886,361 | -429,552 |
| Free Cash Flow | — | — | -251,567 |
| Rev Growth | +20.3% | +20.3% | -1.1% |
| Debt/Equity | — | — | 0.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $254.31 | +0.38% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $360.55 | +0.62% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.33 | -1.21% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $499.65 | +1.69% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $631.81 | -0.17% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.52 | +0.74% | 69.3 | 39.97B |